Your browser doesn't support javascript.
loading
Psychedelic Psychiatry's Brave New World.
Nutt, David; Erritzoe, David; Carhart-Harris, Robin.
Afiliação
  • Nutt D; Centre for Psychedelic Research, Department of Psychiatry, Imperial College London, London W12 0NN, UK. Electronic address: d.nutt@imperial.ac.uk.
  • Erritzoe D; Centre for Psychedelic Research, Department of Psychiatry, Imperial College London, London W12 0NN, UK.
  • Carhart-Harris R; Centre for Psychedelic Research, Department of Psychiatry, Imperial College London, London W12 0NN, UK.
Cell ; 181(1): 24-28, 2020 04 02.
Article em En | MEDLINE | ID: mdl-32243793
ABSTRACT
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psilocibina / Agonistas do Receptor 5-HT2 de Serotonina / Alucinógenos / Transtornos Mentais Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psilocibina / Agonistas do Receptor 5-HT2 de Serotonina / Alucinógenos / Transtornos Mentais Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article